Completed PHASE4 INTERVENTIONAL 1-arm NCT01285050

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

Interferon Alfa Sensitivity in HIV/HCV Coinfected Persons Before and After Antiretroviral Therapy

Sponsor: Johns Hopkins University

Interventions Antiretroviral therapy (ART) Emtricitabine and tenofovir disoproxil fumarate raltegravir

Updated 8 times since 2017 Last updated: Oct 6, 2016 Started: Jan 31, 2011 Primary completion: Apr 30, 2015 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates HIV Infection and Hepatitis C and is currently completed. Johns Hopkins University leads this study, which shows 8 recorded versions since 2011 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johns Hopkins University
National Institute on Drug Abuse (NIDA)

Data source: Johns Hopkins University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States